Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antisense treatments for biothreat agents.

Kelly L Warfield1, Rekha G Panchal, M Javad Aman

  • 1U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD 21702, USA.

Current Opinion in Molecular Therapeutics
|April 14, 2006
PubMed
Summary

Antisense oligomers (ASOs) are advanced nucleic acid therapies showing promise against viral and bacterial infections. This review highlights third-generation phosphorodiamidate morpholino oligomers as a key development for treating biothreat agents.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chikungunya virus virus-like particle vaccine (VIMKUNYA) elicits cross-neutralization across CHIKV lineages and against other alphaviruses after just one dose.

Vaccine·2026
Same author

Chikungunya virus virus-like particle vaccine (Vimkunya) induces a rapid and durable antigen-specific CD4<sup>+</sup> T cell response.

Vaccine·2026
Same author

A chikungunya virus-like particle vaccine reduces chikungunya disease in cynomolgus macaques and protection is mediated by antibody transferred from vaccinated humans.

NPJ vaccines·2026
Same author

Efficacy evaluation of the S-adenosylhomocysteine hydrolase inhibitor MSD-914 in rhesus macaques (Macaca Mulatta) challenged with Ebola virus by the intramuscular route.

PloS one·2026
Same author

Passive transfer of human sera from chikungunya virus virus-like particle vaccine (Vimkunya) recipients fully protects non-human primates from viremia.

NPJ vaccines·2026
Same author

Identification of the seven critical residues that control ZIKV-DENV cross-reactivity to engineer a non-cross-reactive ZIKV vaccine.

Cell reports·2025

Area of Science:

  • Oligonucleotide therapeutics
  • Antimicrobial drug development
  • Biodefense technologies

Background:

  • Antisense oligomers (ASOs) are effective against various pathogens in preclinical models.
  • ASO technology is being developed to combat biothreat agents like Ebola virus, dengue virus, and Bacillus anthracis.
  • Multiple generations of ASOs have been engineered to improve stability, binding affinity, and cellular uptake.

Purpose of the Study:

  • To review the development and applications of antisense oligomer technology.
  • To focus on third-generation phosphorodiamidate morpholino oligomers (PMOs) for treating infections.
  • To discuss the potential of ASOs as a critical defense against dangerous pathogens.

Main Methods:

  • Review of scientific literature on antisense oligomer generations and modifications.

Related Experiment Videos

  • Focus on the chemical structure and properties of third-generation PMOs.
  • Analysis of ASO applications against viral, bacterial, and biothreat agents.

    • Main Results:

    • First-generation ASOs utilize phosphorothioate modifications for stability.
    • Second-generation ASOs incorporate 2'-O-methyl and 2'-O-methoxyethyl modifications to enhance binding and resistance.
    • Third-generation ASOs, including PMOs, offer improved stability, affinity, and bioavailability, with PMOs being nonionic and lacking a ribose ring.

    Conclusions:

    • Antisense oligomer therapeutics are advancing rapidly, with third-generation PMOs showing significant potential.
    • ASOs are poised to become a vital component in the defense against emerging and engineered infectious diseases.
    • The ongoing development of ASO-based drugs strengthens our capacity to address biothreat agents.